Bausch Health Companies Inc. (NYSE:BHC) Director Acquires $3,808,376.70 in Stock

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) Director John Paulson bought 754,134 shares of the business's stock in a transaction that occurred on Tuesday, June 10th. The shares were bought at an average cost of $5.05 per share, for a total transaction of $3,808,376.70. Following the transaction, the director now owns 27,193,169 shares of the company's stock, valued at $137,325,503.45. The trade was a 2.85% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

John Paulson also recently made the following trade(s):

• On Thursday, June 12th, John Paulson bought 1,005,376 shares of Bausch Health Companies stock. The shares were bought at an average cost of $5.47 per share, for a total transaction of $5,499,406.72.
• On Wednesday, June 11th, John Paulson purchased 1,029,098 shares of Bausch Health Companies stock. The shares were acquired at an average price of $5.24 per share, for a total transaction of $5,392,473.52.

Bausch Health Companies Price Performance

Shares of BHC traded up $0.51 during mid-day trading on Friday, hitting $6.02. The stock had a trading volume of 11,490,808 shares, compared to its average volume of 2,611,310. The firm has a market cap of $2.23 billion, a P/E ratio of -50.12, a PEG ratio of 0.37 and a beta of 0.28. The business has a fifty day moving average price of $4.85 and a 200-day moving average price of $6.43. Bausch Health Companies Inc. has a 52 week low of $3.96 and a 52 week high of $9.85.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Royal Bank of Canada boosted their target price on Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Wall Street Zen lowered Bausch Health Companies from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $7.42.

Hedge Funds Weigh In On Bausch Health Companies

A number of hedge funds and other institutional investors have recently modified their holdings of BHC. Nomura Holdings Inc. boosted its holdings in shares of Bausch Health Companies by 106.2% in the 1st quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company's stock worth $151,366,000 after purchasing an additional 12,050,000 shares in the last quarter. Maple Rock Capital Partners Inc. boosted its holdings in shares of Bausch Health Companies by 156.7% in the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock worth $42,718,000 after purchasing an additional 3,235,100 shares in the last quarter. Compass Rose Asset Management LP boosted its holdings in shares of Bausch Health Companies by 366.7% in the 4th quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company's stock worth $16,926,000 after purchasing an additional 1,650,000 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Bausch Health Companies by 46.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock valued at $38,501,000 after acquiring an additional 1,510,445 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in Bausch Health Companies by 4,134.7% during the 1st quarter. Acadian Asset Management LLC now owns 673,316 shares of the company's stock valued at $4,347,000 after acquiring an additional 657,416 shares during the period. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.